Table 2.

Multivariate analysis of overall survival in cohort 1 (pembrolizumab)

				Model 1			Model 2
Factor	N	%	% Dead	HR	95% CI	P	HR	95% CI	P
S100B
≤ 0.3 µg/l	116	76.3	19.0	1			1
> 0.3 µg/l	36	23.7	44.4	2.54	1.20–5.37	0.014	2.93	1.40–6.17	0.005
LDH
≤1.5xULN	130	85.5	21.5	1			1
>1.5xULN	22	14.5	45.5	2.39	1.02–5.59	0.045	2.06	0.89–4.78	0.09
Visceral metastasis
No	54	35.5	9.3	1			1
Yes	98	64.5	33.7	4.04	1.56–10.45	0.004	2.60	0.88–7.65	0.08
CNS metastasis
No	106	69.7	16.0				1
Yes	46	30.3	45.7				2.15	0.98–4.70	0.06
Origin
Cutaneous	119	78.3	26.1	1			1
Occult	17	11.2	23.5	1.01	0.34–3.00	0.98	1.15	0.39–3.41	0.79
Mucosal	8	5.3	25.0	0.52	0.12–2.23	0.38	0.72	0.16–3.20	0.67
Uveal	8	5.3	12.5	0.51	0.07–3.87	0.51	0.86	0.10–7.14	0.89

CI confidence interval, CNS central nervous system, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value